{"nctId":"NCT00275821","briefTitle":"Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)","startDateStruct":{"date":"2005-12"},"conditions":["Age Related Macular Degeneration"],"count":353,"armGroups":[{"label":"Ranibizumab 0.3 mg - 3 times monthly, then quarterly","type":"EXPERIMENTAL","interventionNames":["Drug: Ranibizumab 0.3 mg - 3 times monthly, then quarterly"]},{"label":"Ranibizumab 0.5 mg - 3 times monthly, then quarterly","type":"EXPERIMENTAL","interventionNames":["Drug: Ranibizumab 0.5 mg - 3 times monthly, then quarterly"]},{"label":"Ranibizumab 0.3 mg monthly","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ranibizumab 0.3 mg monthly"]}],"interventions":[{"name":"Ranibizumab 0.3 mg - 3 times monthly, then quarterly","otherNames":[]},{"name":"Ranibizumab 0.5 mg - 3 times monthly, then quarterly","otherNames":[]},{"name":"Ranibizumab 0.3 mg monthly","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with primary or recurrent subfoveal CNV secondary to AMD, including those with predominantly classic, minimally classic or occult lesions with no classic component\n* Patients who have a BCVA score between 73 and 24 letters, inclusively, in the study eye using ETDRS-like grading charts (approximately 20/40 to 20/320)\n\nExclusion Criteria:\n\n* Prior treatment in the study eye with verteporfin, external-beam radiation therapy, subfoveal focal laser photocoagulation, vitrectomy, or transpupillary thermotherapy.\n* History of submacular surgery or other surgical intervention for AMD in the study eye, glaucoma filtration surgery, corneal transplant surgery.\n* Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within one month preceding Baseline.\n\nOther protocol-defined inclusion/exclusion criteria applied to the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change From Baseline in Best-corrected Visual Acuity of the Study Eye at Month 12","description":"Visual acuity (VA) was assessed in both eyes at each study visit using best correction determined from protocol refraction. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at an initial testing distance of 4 meters.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","spread":"13.13"},{"groupId":"OG001","value":"3.8","spread":"13.33"},{"groupId":"OG002","value":"8.3","spread":"11.31"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in the Total Lesion Area of the Study Eye at Month 12","description":"Fluorescein angiography was conducted in conjunction with color fundus photography at screening and at Months 6 and 12. Investigators used digital fluorescein angiograms to determine presence or absence of choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.21","spread":"5.616"},{"groupId":"OG001","value":"-1.51","spread":"4.802"},{"groupId":"OG002","value":"-1.28","spread":"4.367"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Retinal Thickness at the Central Point of the Study Eye at Month 12","description":"Optical Coherence Tomography (OCT) was performed on both eyes at screening and monthly from baseline through Month 12 prior to study drug administration. OCT images were evaluated at the central reading center (CRC) by trained graders and ophthalmologists experienced in clinical trials.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-96.0","spread":"96.82"},{"groupId":"OG001","value":"-105.6","spread":"128.98"},{"groupId":"OG002","value":"-105.3","spread":"128.55"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Retinal Thickness at the Central Subfield of the Study Eye at Month 12","description":"Optical Coherence Tomography (OCT) was performed on both eyes at screening and monthly from baseline through Month 12 prior to study drug administration. OCT images were evaluated at the central reading center (CRC) by trained graders and ophthalmologists experienced in clinical trials.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-93.3","spread":"100.88"},{"groupId":"OG001","value":"-97.5","spread":"117.52"},{"groupId":"OG002","value":"-97.9","spread":"112.47"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":15,"n":120},"commonTop":["Eye pain (Study eye)","Conjunctival haemorrhage (Study eye)","Visual acuity reduced (Study eye)","Intraocular pressure increased (Study eye)","Ocular hyperaemia (Study eye)"]}}}